5 Of The Best-Performing Biotech Stocks Of 2017
bluebird’s shares have been gaining following the presentation of data at the annual meeting of the American Society of Clinical Oncology (“ASCO”) earlier this year in June. Shares shot up further in August when Gilead announced its intention to acquire immuno-oncology focused Kite Pharma. The Gilead-Kite deal has raised hopes for additional acquisition deals in the immuno-oncology therapeutic area with bluebird considered to be an attractive acquisition target. bluebird is also a Zacks Rank #3 stock and its shares are up 191.6% year to date.
.
Disclosure: Zacks.com contains statements and statistics that have been obtained from sources believed to be reliable but are not guaranteed as to accuracy or completeness. References to any ...
more
How did you like this article? Let us know so we can better customize your reading experience.
Users' ratings are only visible to themselves.
Comments
Leave a comment to automatically be entered into
our contest to win a free Echo Show.
